Nexentis Technologies Stock

NXTS

US80512Q6008

Market Closed - Nasdaq 01:00:00 07/11/2026 +04			5-day change	1st Jan Change
0.5142 ^USD	+6.79%		-82.43%	-99.13%

08-14	Nexentis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-23	Top Midday Decliners	MT

Valuation: Nexentis Technologies

Market Cap	3.74M 3.35M 3.06M 2.8M 5.27M 351M 5.43M 36.92M 14.72M 187M 14.03M 13.72M 592M	P/E 2024	-0.28x	P/E 2025	-0.34x
Enterprise Value	658K 590K 539K 492K 927K 61.81M 956K 6.5M 2.59M 32.98M 2.47M 2.42M 104M	EV / Sales 2024	55.5x	EV / Sales 2025	-
Free-Float	-	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news: Nexentis Technologies

08-14	Nexentis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-23	Top Midday Decliners	MT
06-23	Top Premarket Decliners	MT
06-22	Top Midday Gainers	MT
05-28	Nexentis Technologies Inc. Approves Amendment to A Facility Agreement	CI
05-15	Nexentis Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-17	Nexentis Technologies Inc - may offer up to $100 million of securities - SEC filing	RE
04-01	Nexentis Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	Nexentis Technologies Inc. Auditor Raises 'Going Concern' Doubt	CI
03-15	Voice Assist, Inc. completed the acquisition of 98% stake in Save Foods Ltd. from N2OFF, Inc..	CI
02-26	N2OFF, Inc. will Change its Ticker to NXTS from NITO	CI
02-26	N2OFF, Inc. will Change its Name to Nexentis Technologies Inc	CI
02-26	Nexentis Technologies Inc. will Change its Ticker to NXTS from NITO	CI

More news

Press Releases: Nexentis Technologies

10-07	Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud	AQ
09-24	Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board	AQ
09-23	Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery	AQ
07-28	Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign	AQ
07-07	Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative	AQ

More press releases

Managers and Directors: Nexentis Technologies

Manager	Title	Age	Since
David Palach CEO	Chief Executive Officer	60	05/11/2020
Lital Barda DFI	Director of Finance/CFO	39	18/04/2022
Michal Efraty IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Ronen Rosenbloom BRD	Director/Board Member	54	26/08/2020
Amitay Weiss CHM	Chairman	62	24/05/2021
Israel Berenshtein BRD	Director/Board Member	54	26/08/2020

More insiders

Nexentis Technologies Inc, formerly known as N2OFF, Inc., is an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. Through its subsidiary MitoCareX Bio Ltd. The company uses a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure guided virtual screening workflows. MITOLINE, its proprietary computational platform, is designed to allow proper homology modeling of mitochondrial membrane proteins, particularly transport proteins. It enables three-dimensional structural modeling and large-scale virtual screening, MITOLINE opens access to a novel untapped target space, allowing the Company to identify small-molecule modulators that directly disrupt cancer metabolism with the potential of minimizing systemic toxicity.

Employees

Sector

Calendar

11-09 Significant Split/Dividend

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	$2.571	+6.79%	45,841
05/11/26	$2.408	-13.24%	38,707
04/11/26	$2.775	-2.46%	13,410
03/11/26	$2.845	+7.08%	9,795
02/11/26	$2.657	-9.21%	11,631

Delayed Quote Nasdaq

More quotes

1 day	+6.79%
1 week	-82.43%
Current month	-82.43%
1 month	-90.48%
3 months	-94.56%
6 months	-98.24%
Current year	-99.13%

1 week	0.48	2.9
1 month	0.48	4.8
Current year	0.48	119
1 year	0.48	119
3 years	0.48	9,248.64
5 years	0.48	75,031.36
10 years	0.48	270,124.26

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/02/26	Lital Barda	Free	Chief Financial Officer	50,000	1.8639%
09/02/26	Amitay Weiss	Free	Chairman	116,286	4.3350%
09/02/26	David Palach	Free	Chief Executive Officer	100,000	3.7279%

	2024	2025
Net sales	210K 188K 172K 157K 296K 19.74M 305K 2.07M 827K 10.53M 788K 771K 33.25M	-
Net income	-5.19M -4.66M -4.26M -3.89M -7.32M -488M -7.55M -51.31M -20.46M -260M -19.49M -19.07M -822M	-4M -3.59M -3.28M -3M -5.64M -376M -5.82M -39.56M -15.77M -201M -15.03M -14.71M -634M
Net Debt	-2.48M -2.23M -2.04M -1.86M -3.5M -234M -3.61M -24.55M -9.79M -125M -9.33M -9.13M -393M	-3.08M -2.76M -2.52M -2.3M -4.34M -289M -4.48M -30.42M -12.13M -154M -11.56M -11.31M -488M

Nexentis Technologies Stock

Stocks

NXTS

US80512Q6008

Valuation: Nexentis Technologies

Chart: Nexentis Technologies

Latest news: Nexentis Technologies

Press Releases: Nexentis Technologies

Quotes and Performance

Price Extremes

Managers and Directors: Nexentis Technologies

Latest insider transactions

Financials

Company Profile

Quotes

Markets		Quality
Nasdaq	NXTS	Delayed
CBOE	NXTS	Real-time